# A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

> **NCT06234462** · PHASE2 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Long COVID
- Post-Acute COVID-19 Syndrome

## Interventions

- **DRUG:** Amantadine
- **OTHER:** Physical, Occupational, Speech Therapy
- **OTHER:** Provider Counseling
- **OTHER:** Medications for symptoms management

## Key facts

- **NCT ID:** NCT06234462
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** challenges with recruitment
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06234462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06234462, "A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06234462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*